Biostar Pharmaceuticals, Inc.
BSPM
BSPM was delisted on the 18th of September, 2018.
13 hedge funds and large institutions have $1.04M invested in Biostar Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
30% more funds holding
Funds holding: 10 → 13 (+3)
25% less capital invested
Capital invested by funds: $1.39M → $1.04M (-$352K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$47.7K |
| 2 |
Jane Street
New York
|
+$38.1K |
| 3 |
Renaissance Technologies
New York
|
+$35.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.8K |
| 5 |
Citigroup
New York
|
+$353 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
-$54K |
| 2 |
SIM
Spark Investment Management
New York
|
-$28.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$20.1K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$6.31K |
| 5 |
Morgan Stanley
New York
|
-$5.29K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $817K | +$35.7K | +3,228 | +4% |
|
|
SIM
2
Spark Investment Management
New York
| $59K | -$28.1K | -2,543 | -30% |
|
|
EGA
3
Eagle Global Advisors
Houston,
Texas
| $44K | +$47.7K | +4,316 | New |
|
|
4
Jane Street
New York
| $35K | +$38.1K | +3,451 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $22K | +$23.8K | +2,157 | New |
|
6
California Public Employees Retirement System
Sacramento,
California
| $20K | – | – | – |
|
|
AL
7
Airain Ltd
St. Peter Port,
Guernsey
| $17K | – | – | – |
|
|
VKH
8
Virtu KCG Holdings
New York
| $16K | +$353 | +32 | +2% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4K | -$20.1K | -1,817 | -84% |
|
|
U
10
UBS
Zurich,
Switzerland
| $1K | -$6.31K | -571 | -83% |
|
11
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
N
12
Natixis
Paris,
France
| – | -$54K | -3,829 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$5.29K | -479 | -95% |
|
|
14
Citigroup
New York
| – | +$353 | +32 | New |
|
BSPM Hedge Fund Activity: Q2 2014 in Review
13 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q2 2014, worth a combined $1.04M — down 25% from $1.39M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BSPM positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Eagle Global Advisors, opening a new position worth an estimated $47.7K. The largest seller was Natixis, exiting entirely with an estimated $54K sold.
- 13 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q2 2014, up from 10 in Q1 2014.
- Funds reported $1.04M of Biostar Pharmaceuticals, Inc. stock for Q2 2014, down 25% quarter-over-quarter.
- 4 funds opened new Biostar Pharmaceuticals, Inc. positions in Q2 2014 and 1 closed out, a net change of +3 holders.
- The largest Biostar Pharmaceuticals, Inc. buyer in Q2 2014 was Eagle Global Advisors, an estimated $47.7K added.
- The largest Biostar Pharmaceuticals, Inc. seller in Q2 2014 was Natixis, an estimated $54K sold.
Based on aggregated 13F filings for Q2 2014.